Yahoo · Oct 15, 2026
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks:Stock Name Volume High Low Last Change Stardust Power Inc.
DR
NASDAQ · DRMA
Dermata Therapeutics, Inc.
Healthcare · Biotechnology
$0.86
Up+$0.06 (+8.07%)
Updated Oct 23, 2026, 2:35 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.9M
- P/E ratio
- -0.32
- Dividend yield
- 0.00%
- 52-week range
- $0.60 – $4.66
- Volume
- 140.28K
- Avg. volume
- 196.69K
Price performance · DRMA
DRMA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
DRMA closed at $0.86 after 21 trading sessions, down 26.15% for the selected period.
- Last close
- $0.86
- Period change
- -26.15%
- Period low
- $0.66
- Period high
- $1.17
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $0.78 | $0.87 | $0.78 | $0.864 | 140.28K |
| Oct 21, 2026 | $0.8501 | $0.8898 | $0.7817 | $0.7995 | 222.82K |
| Oct 20, 2026 | $0.8554 | $0.9275 | $0.83 | $0.8699 | 185.13K |
| Oct 19, 2026 | $0.8478 | $0.9701 | $0.76 | $0.8599 | 852.47K |
| Oct 16, 2026 | $0.909 | $0.9504 | $0.81 | $0.86 | 2.52M |
| Oct 15, 2026 | $0.7685 | $1.18 | $0.7658 | $0.91 | 170.52M |
| Oct 14, 2026 | $0.86 | $0.86 | $0.6032 | $0.6633 | 350.75K |
| Oct 13, 2026 | $0.8901 | $0.90 | $0.84 | $0.8599 | 40.09K |
| Oct 12, 2026 | $1.0001 | $1.0102 | $0.8867 | $0.8896 | 44.91K |
| Oct 9, 2026 | $1.08 | $1.08 | $1.01 | $1.02 | 22.52K |
| Oct 8, 2026 | $1.10 | $1.10 | $1.05 | $1.07 | 7.1K |
| Oct 7, 2026 | $1.14 | $1.14 | $1.11 | $1.12 | 7.42K |
| Oct 6, 2026 | $1.12 | $1.145 | $1.11 | $1.13 | 29.59K |
| Oct 5, 2026 | $1.16 | $1.16 | $1.0901 | $1.11 | 14.16K |
| Oct 2, 2026 | $1.16 | $1.16 | $1.08 | $1.105 | 18.31K |
| Oct 1, 2026 | $1.08 | $1.1298 | $1.06 | $1.11 | 21.05K |
| Sep 30, 2026 | $1.10 | $1.12 | $1.10 | $1.10 | 15.15K |
| Sep 29, 2026 | $1.12 | $1.175 | $1.1153 | $1.13 | 10.51K |
| Sep 28, 2026 | $1.14 | $1.16 | $1.10 | $1.12 | 25.08K |
| Sep 25, 2026 | $1.15 | $1.20 | $1.13 | $1.14 | 30.32K |
| Sep 24, 2026 | $1.15 | $1.25 | $1.12 | $1.17 | 78.1K |
Latest DRMA news
The latest Smart Investors Daily articles mentioning DRMA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DRMA research
Overview
Company profile and research snapshot.
Company profile
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2025 | Maxim Group | Buy | — |
| May 21, 2025 | Maxim Group | Buy | — |
| Aug 21, 2024 | Maxim Group | Buy | — |
| Mar 23, 2023 | Maxim Group | Buy | — |
| Sep 21, 2021 | Brookline Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 15, 2026
Why Is Dermata Therapeutics Stock Gaining Thursday?
Dermata Therapeutics (DRMA) jumps 34% after positive clinical results for its weekly Bioneedle Tome Foundational Treatment.
Yahoo · Oct 15, 2026
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
\- Once-weekly Tome Foundational Treatment demonstrated improvements across key measures of skin appearance after four treatments -\- Over 71% of study participants were graded as having overall improvements in their skin after only one treatment -\- Tome Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time -SAN DIEGO, CA / ACCESS Newswire / October 15, 2026 / , Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in derma
Benzinga · Oct 15, 2026
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
